Solid Biosciences to Present at the Chardan Genetic Medicines Conference
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.
Media Contact:
Kate Niazi-Sai
617-337-4680
media@solidbio.com
Investor Contact:
Kendall Investor Relations
617-337-4680
investors@solidbio.com
Source: Solid Biosciences Inc.